Biotech Values

[jbog]

Vivus hits a homerun

VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities

Highlights from the EQUIP and CONQUER studies include:


Average weight loss of 14.7% (37 lbs) was achieved by patients treated with Qnexa for 56 weeks in the EQUIP study;
Significant improvements in cardiovascular, metabolic and inflammatory risk factors among patients treated with Qnexa;
FDA efficacy benchmarks for weight loss agents exceeded at all three doses of Qnexa tested in the clinical program;
Completion rates up to 69% were significantly higher than placebo at all three doses of Qnexa, indicating favorable tolerability; and
Favorable benefit/risk safety profile for Qnexa.

http://finance.yahoo.com/news/VIVUS-Announces-Positive-prnews-2043203647.html?x=0&.v=1